Patient characteristics
| Patient characteristics . | N . | % . |
|---|---|---|
| Total | 107 | |
| Age, median (range), y | 62 (19, 73) | |
| Patient-donor sex | ||
| M-M | 47 | 43.9 |
| M-F | 18 | 16.8 |
| F-M | 23 | 21.5 |
| F-F | 19 | 17.8 |
| Diagnosis | ||
| AML | 37 | 34.6 |
| MDS | 24 | 22.4 |
| NHL | 12 | 11.2 |
| MPD | 7 | 6.5 |
| CLL/SLL/PLL | 6 | 5.6 |
| ALL | 5 | 4.7 |
| Mixed MDS/MPD | 4 | 3.7 |
| CML | 2 | 1.9 |
| Hodgkin disease | 3 | 2.8 |
| MM/PCD | 4 | 3.7 |
| Anemia/red cell disorder | 2 | 1.9 |
| Immunodeficiency | 1 | 0.9 |
| Disease risk index | ||
| Low | 17 | 15.9 |
| Intermediate | 46 | 43 |
| High | 37 | 34.6 |
| Donor HLA type | ||
| Matched unrelated | 66 | 61.7 |
| Matched related | 30 | 28 |
| Mismatch unrelated | 11 | 10.3 |
| Stem cell source | ||
| PBSCs | 99 | 92.5 |
| Bone marrow | 7 | 6.5 |
| Bone marrow and PBSCs | 1 | 0.9 |
| Acute GVHD prophylaxis | ||
| Tac-Sir-MTX | 74 | 69.2 |
| Tac-Sir | 24 | 22.4 |
| Tac-MTX | 8 | 7.5 |
| Sir-MMF-MTX | 1 | 0.9 |
| Acute GVHD grade | ||
| 0 | 63 | 58.9 |
| I | 12 | 11.2 |
| II | 16 | 15 |
| III | 15 | 14 |
| IV | 1 | 0.9 |
| Chronic GVHD | ||
| None | 61 | 57 |
| Extensive | 42 | 39.3 |
| Limited | 4 | 3.7 |
| Patient characteristics . | N . | % . |
|---|---|---|
| Total | 107 | |
| Age, median (range), y | 62 (19, 73) | |
| Patient-donor sex | ||
| M-M | 47 | 43.9 |
| M-F | 18 | 16.8 |
| F-M | 23 | 21.5 |
| F-F | 19 | 17.8 |
| Diagnosis | ||
| AML | 37 | 34.6 |
| MDS | 24 | 22.4 |
| NHL | 12 | 11.2 |
| MPD | 7 | 6.5 |
| CLL/SLL/PLL | 6 | 5.6 |
| ALL | 5 | 4.7 |
| Mixed MDS/MPD | 4 | 3.7 |
| CML | 2 | 1.9 |
| Hodgkin disease | 3 | 2.8 |
| MM/PCD | 4 | 3.7 |
| Anemia/red cell disorder | 2 | 1.9 |
| Immunodeficiency | 1 | 0.9 |
| Disease risk index | ||
| Low | 17 | 15.9 |
| Intermediate | 46 | 43 |
| High | 37 | 34.6 |
| Donor HLA type | ||
| Matched unrelated | 66 | 61.7 |
| Matched related | 30 | 28 |
| Mismatch unrelated | 11 | 10.3 |
| Stem cell source | ||
| PBSCs | 99 | 92.5 |
| Bone marrow | 7 | 6.5 |
| Bone marrow and PBSCs | 1 | 0.9 |
| Acute GVHD prophylaxis | ||
| Tac-Sir-MTX | 74 | 69.2 |
| Tac-Sir | 24 | 22.4 |
| Tac-MTX | 8 | 7.5 |
| Sir-MMF-MTX | 1 | 0.9 |
| Acute GVHD grade | ||
| 0 | 63 | 58.9 |
| I | 12 | 11.2 |
| II | 16 | 15 |
| III | 15 | 14 |
| IV | 1 | 0.9 |
| Chronic GVHD | ||
| None | 61 | 57 |
| Extensive | 42 | 39.3 |
| Limited | 4 | 3.7 |
ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CMV, cytomegalovirus; F, female; HLA, human leukocyte antigen; M, male; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMF, mycophenolate mofetil; MPD, myeloproliferative disease; MTX, methotrexate; NHL, non-Hodgkin lymphoma; PBSC, peripheral blood stem cell; PCD, plasma cell dyscrasias; PLL, prolymphocytic leukemia; Sir, sirolimus/rapamycin; SLL, small lymphocytic lymphoma; Tac, tacrolimus.